EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January–June 2021

Kathryn Peebles, Robert J Arciuolo, Anthony S Romano, Jessica Sell, Sharon K Greene, Sungwoo Lim, Candace Mulready-Ward, Alexandra Ternier, Brittan Badenhop, Kathleen Blaney, Joseph E Real, Magdalene Spencer und 5 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiac448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Kathryn Peebles und 16 weiteren Autor:innen. Beteiligte Einrichtung: Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence is accumulating of coronavirus disease 2019 (COVID-19) vaccine effectiveness among persons with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Methods

We evaluated the effect against incident SARS-CoV-2 infection of (1) prior infection without vaccination, (2) vaccination (2 doses of Pfizer-BioNTech COVID-19 vaccine) without prior infection, and (3) vaccination after prior infection, all compared with unvaccinated persons without prior infection. We included long-term care facility staff in New York City aged <65 years with weekly SARS-CoV-2 testing from 21 January to 5 June 2021. Test results were obtained from state-mandated laboratory reporting. Vaccination status was obtained from the Citywide Immunization Registry. Cox proportional hazards models adjusted for confounding with inverse probability of treatment weights.

Results

Compared with unvaccinated persons without prior infection, incident SARS-CoV-2 infection risk was lower in all groups: 54.6% (95% confidence interval, 38.0%–66.8%) lower among unvaccinated, previously infected persons; 80.0% (67.6%–87.7%) lower among fully vaccinated persons without prior infection; and 82.4% (70.8%–89.3%) lower among persons fully vaccinated after prior infection.

Conclusions

Two doses of Pfizer-BioNTech COVID-19 vaccine reduced SARS-CoV-2 infection risk by ≥80% and, for those with prior infection, increased protection from prior infection alone. These findings support recommendations that all eligible persons, regardless of prior infection, be vaccinated against COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansBNT162 VaccineCOVID-19 TestingLong-Term CareNew York CitySARS-CoV-2Nursing Homes

Stichwörter der Autor:innen

COVID-19 vaccine effectivenessSARS-CoV-2 reinfectionlong-term care facilities

Substanzen

COVID-19 VaccinesBNT162 Vaccine

Autor:innen und Institutionen

  • Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Division of Epidemiology, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
  • Division of Disease Control, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
  • Division of Family and Child Health, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
  • Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Zitieren

APA

Peebles, K., Arciuolo, R. J., Romano, A. S., Sell, J., Greene, S. K., Lim, S., Mulready-Ward, C., Ternier, A., Badenhop, B., Blaney, K., Real, J. E., Spencer, M., McPherson, T. D., Ahuja, S. D., Sullivan Meissner, J., Zucker, J. R., & Rosen, J. B. (2023). Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January–June 2021. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac448

Vancouver

Peebles K, Arciuolo RJ, Romano AS, Sell J, Greene SK, Lim S, et al. Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January–June 2021. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac448

BibTeX
@article{Peebles2023,
  author = {Peebles, Kathryn and Arciuolo, Robert J and Romano, Anthony S and Sell, Jessica and Greene, Sharon K and Lim, Sungwoo and Mulready-Ward, Candace and Ternier, Alexandra and Badenhop, Brittan and Blaney, Kathleen and Real, Joseph E and Spencer, Magdalene and McPherson, Tristan D and Ahuja, Shama Desai and Sullivan Meissner, Jeanne and Zucker, Jane R and Rosen, Jennifer B},
  title = {Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January–June 2021},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiac448}
}
Kostenlos starten →